©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Sep 20, 2023; 13(4): 95-98
Published online Sep 20, 2023. doi: 10.5493/wjem.v13.i4.95
Published online Sep 20, 2023. doi: 10.5493/wjem.v13.i4.95
Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis
Marco Zeppieri, Department of Ophthalmology, University Hospital of Udine, Udine 33100, Italy
Author contributions: Zeppieri M contributed to all aspects of this manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Marco Zeppieri, BSc, MD, PhD, Doctor, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy.
Received: April 21, 2023
Peer-review started: April 21, 2023
First decision: May 15, 2023
Revised: May 16, 2023
Accepted: June 16, 2023
Article in press: June 16, 2023
Published online: September 20, 2023
Processing time: 147 Days and 0.9 Hours
Peer-review started: April 21, 2023
First decision: May 15, 2023
Revised: May 16, 2023
Accepted: June 16, 2023
Article in press: June 16, 2023
Published online: September 20, 2023
Processing time: 147 Days and 0.9 Hours
Core Tip
Core Tip: Hydroxychloroquine (HCQ) is typically considered when treating rheumatic and autoimmune diseases. It has been currently considered to help treat symptoms of coronavirus disease 2019 and to help alleviate several clinical manifestations after infection. In this letter, several ophthalmological implications that should be taken into consideration when using this drug are discussed. While the drug may be beneficial in treating symptoms, ophthalmological manifestations can be of clinical importance. Proper diagnoses, periodic testing, and correct management of patients in chronic treatment with HCQ can ensure that any potential ophthalmological side effects are minimized.